Orelabrutinib

奥布替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameOrelabrutinib
Drug Alias Name宜诺凯INNOBRUKAYINUOKAIICP-022BIIB-135
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsHelicobacter pylori infectionCentral Nervous System LymphomaLupus Erythematosus, Systemic +[19] 
Global Approved IndicationsLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryMainland China
Original Approved Date2020/12/25
Country/TerritoryUnited StatesUkraineSingapore +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Innocare Pharma Tech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPeking Union Medical College HospitalBiogen IncFudan University +[7] 
Inactive CompaniesInnoCare Pharma IncShandong UniversityInnocare Pharma Australia Pty Ltd
Active IndicationsHelicobacter pylori infectionCentral Nervous System LymphomaLupus Erythematosus, Systemic +[19] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XE
Related LinksDrugBank